Molecular Cancer

Article	Citations
Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives	926
Circular RNA: metabolism, functions and interactions with proteins	638
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions	542
Targeting STAT3 in Cancer Immunotherapy	522
mRNA vaccine for cancer immunotherapy	520
Ferroptosis in cancer therapy: a novel approach to reversing drug resistance	507
The cancer metabolic reprogramming and immune response	495
Targeting TGF-β signal transduction for fibrosis and cancer therapy	366
Glioma targeted therapy: insight into future of molecular approaches	353
Exosomes as a new frontier of cancer liquid biopsy	344
Wnt signaling in colorectal cancer: pathogenic role and therapeutic target	316
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments	314
Exosome-based immunotherapy: a promising approach for cancer treatment	287
Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy	287
The role of m6A RNA methylation in cancer metabolism	286
G-quadruplexes: a promising target for cancer therapy	281
The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities	276
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities	275
Lung cancer immunotherapy: progress, pitfalls, and promises	256
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer	250
The role of ubiquitination and deubiquitination in cancer metabolism	231
mRNA vaccine: a potential therapeutic strategy	222
Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments	221
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc	219
Cuproptosis: mechanisms and links with cancers	213

mRNA therapeutics in cancer immunotherapy	204
Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies	192
N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer	190
m6A modification: recent advances, anticancer targeted drug discovery and beyond	187
Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer	185
Long noncoding RNAs: functions and mechanisms in colon cancer	185
N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling	182
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer	182
Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine	181
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer	179
Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation	172
METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer	166
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer	164
cGAS-STING pathway in cancer biotherapy	162
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments	162
Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring	159
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook	158
Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer	147
Cancer associated-fibroblast-derived exosomes in cancer progression	147
EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3	146
circCUL2 regulates gastric cancer malignant transformation and cisplatin resistance by modulating autophagy activation via miR-142-3p/ROCK2	145
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy	142
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances	141
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer	140
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing	138
The circular RNA circ-ERBIN promotes growth and metastasis of colorectal cancer by miR-125a-5p and miR-138-5p/4EBP-1 mediated cap-independent HIF-1α translation	132
A novel protein encoded by circMAPK1 inhibits progression of gastric cancer by suppressing activation of MAPK signaling	131
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy	129
Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis	126
Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC	123
CircECE1 activates energy metabolism in osteosarcoma by stabilizing c-Myc	118
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer	118
Circular RNA hsa_circ_0004872 inhibits gastric cancer progression via the miR-224/Smad4/ADAR1 successive regulatory circuit	116
Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis	115
Proteolysis-targeting chimeras (PROTACs) in cancer therapy	115
Advancements in nanoparticle-based treatment approaches for skin cancer therapy	115
Circ3823 contributes to growth, metastasis and angiogenesis of colorectal cancer: involvement of miR-30c-5p/TCF7 axis	113
Insights into N6-methyladenosine and programmed cell death in cancer	113
DDX3X: structure, physiologic functions and cancer	113
Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer	112
Targeting the RNA m6A modification for cancer immunotherapy	111
Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer	111
LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM	109
METTL14-mediated m6A modification of circORC5 suppresses gastric cancer progression by regulating miR-30c-2-3p/AKT1S1 axis	107
Non-coding RNAs regulation of macrophage polarization in cancer	107
Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer	104
Targeting the tumor stroma for cancer therapy	103
Comprehensive landscape and future perspectives of circular RNAs in colorectal cancer	101
The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition	101
Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification	100

Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development	99
Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab	99
Proteomics technologies for cancer liquid biopsies	99
circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway	99
Clinical and immunological effects of mRNA vaccines in malignant diseases	98
M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma	97
Tumor-associated exosomes promote lung cancer metastasis through multiple mechanisms	96
Exosomal circLPAR1 functions in colorectal cancer diagnosis and tumorigenesis through suppressing BRD4 via METTL3–eIF3h interaction	96
Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin	95
Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma	95
The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies	94
A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study	94
The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy	94
Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development	93
Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma	90
Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m6A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression	90
Molecular mechanisms of tumor resistance to radiotherapy	90
The circular RNA circSPARC enhances the migration and proliferation of colorectal cancer by regulating the JAK/STAT pathway	89
Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer	89
CircPTPRA blocks the recognition of RNA N6-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression	88
Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential	88
CircDIDO1 inhibits gastric cancer progression by encoding a novel DIDO1-529aa protein and regulating PRDX2 protein stability	86
Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications	86
Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell?	84
Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy	84
Plasma-derived exosomal miR-15a-5p as a promising diagnostic biomarker for early detection of endometrial carcinoma	82
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers	82
Targeting KRAS mutant cancers: from druggable therapy to drug resistance	82
Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p	80
The m6A RNA methylation regulates oncogenic signaling pathways driving cell malignant transformation and carcinogenesis	80
CircIL4R activates the PI3K/AKT signaling pathway via the miR-761/TRIM29/PHLPP1 axis and promotes proliferation and metastasis in colorectal cancer	80
Circular RNA circIPO11 drives self-renewal of liver cancer initiating cells via Hedgehog signaling	79
Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications	79
LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer	78
CD39/CD73/A2AR pathway and cancer immunotherapy	78
The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p	78
The journey of CAR-T therapy in hematological malignancies	78
A novel protein AXIN1-295aa encoded by circAXIN1 activates the Wnt/β-catenin signaling pathway to promote gastric cancer progression	76
Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis	76
A novel peptide encoded by N6-methyladenosine modified circMAP3K4 prevents apoptosis in hepatocellular carcinoma	75
CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway	75
FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2	74
The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin	74
CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing	74
Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer	73
CircGPR137B/miR-4739/FTO feedback loop suppresses tumorigenesis and metastasis of hepatocellular carcinoma	73
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma	73
Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance	72
Delivery of cancer therapies by synthetic and bio-inspired nanovectors	72
Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO2	72
LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway	71
ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma	71
circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis	71
Epigenetic silencing of miR-144/451a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling	71
Potential clinical utility of liquid biopsies in ovarian cancer	70
Gold nanoparticles and gold nanorods in the landscape of cancer therapy	70
Comprehensive analyses of m6A regulators and interactive coding and non-coding RNAs across 32 cancer types	70
The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors	69
Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy	69
Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades	68
RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment	68
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers	66
Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m6A-mediated degradation of STEAP3 mRNA	66
Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer	66
Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer	65
Histone citrullination: a new target for tumors	65
Crosstalk between N6-methyladenosine modification and circular RNAs: current understanding and future directions	64
Long non-coding RNA LINC00680 functions as a ceRNA to promote esophageal squamous cell carcinoma progression through the miR-423-5p/PAK6 axis	64
CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer	64
The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer	63
Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy	63
The functional roles of the circRNA/Wnt axis in cancer	63
The role and application of small extracellular vesicles in gastric cancer	63
Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing	62
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer	62
A clinician’s handbook for using ctDNA throughout the patient journey	60
Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis	60
The potential roles of exosomes in pancreatic cancer initiation and metastasis	59
Regulatory cells and the effect of cancer immunotherapy	59
Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA	59

CircMYH9 drives colorectal cancer growth by regulating serine metabolism and redox homeostasis in a p53-dependent manner	59
CircBCAR3 accelerates esophageal cancer tumorigenesis and metastasis via sponging miR-27a-3p	59
Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer	59
Clinical significance of FBXW7 loss of function in human cancers	58
Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-κB/bone remodeling factors signaling	58
Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy	58
circPTEN1, a circular RNA generated from PTEN, suppresses cancer progression through inhibition of TGF-β/Smad signaling	58
NK cells and solid tumors: therapeutic potential and persisting obstacles	57
CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502–5p/KRAS and IGF2BP2/Myc axes	57
CircEZH2/miR-133b/IGF2BP2 aggravates colorectal cancer progression via enhancing the stability of m6A-modified CREB1 mRNA	57
Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials	57
The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells	57
A novel class of tsRNA signatures as biomarkers for diagnosis and prognosis of pancreatic cancer	57
Diagnostic efficacy of circular RNAs as noninvasive, liquid biopsy biomarkers for early detection of gastric cancer	56
RNA-based therapies: A cog in the wheel of lung cancer defense	56
The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC	56
Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion	55
Crosstalk between 5-methylcytosine and N6-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma	55
Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses	55
CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSα/ATM-p73 axis in bladder cancer	54
Circular RNAs’ cap-independent translation protein and its roles in carcinomas	54
Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma	54
The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma	53
CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma	53
Cancer-associated fibroblast-derived gene signatures determine prognosis in colon cancer patients	53
Small extrachromosomal circular DNA (eccDNA): major functions in evolution and cancer	53
Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression	53
Hypoxia-induced circWSB1 promotes breast cancer progression through destabilizing p53 by interacting with USP10	52
Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy	52
CircDOCK1 promotes the tumorigenesis and cisplatin resistance of osteogenic sarcoma via the miR-339-3p/IGF1R axis	52
The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis	52
Nanomaterials in tumor immunotherapy: new strategies and challenges	52
Expanding uncapped translation and emerging function of circular RNA in carcinomas and noncarcinomas	52
mRNA in cancer immunotherapy: beyond a source of antigen	51
Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis	50
Crosstalk between autophagy inhibitors and endosome-related secretory pathways: a challenge for autophagy-based treatment of solid cancers	50
N6-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell carcinoma	50
Reprogramming the tumor microenvironment by genome editing for precision cancer therapy	50
Tumor-suppressive circRHOBTB3 is excreted out of cells via exosome to sustain colorectal cancer cell fitness	50
Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy	50
Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance	49
Hypoxia downregulated miR-4521 suppresses gastric carcinoma progression through regulation of IGF2 and FOXM1	49
Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication	49
Clinical application and detection techniques of liquid biopsy in gastric cancer	49
New frontiers in immune checkpoint B7-H3 (CD276) research and drug development	48
A novel NF-κB regulator encoded by circPLCE1 inhibits colorectal carcinoma progression by promoting RPS3 ubiquitin-dependent degradation	48
SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions	48
Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment	47
Nonsense-mediated RNA decay and its bipolar function in cancer	46
Clinical considerations for the design of PROTACs in cancer	45
The intersection of COVID-19 and cancer: signaling pathways and treatment implications	45
Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer	45
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges	45